Evolent Q4 2025 revenue $468.7M, net loss $429.1M; guides 2026 revenue up ~30%

Evolent Health, Inc.

2025-FY EPS reported -$5.07 revenue$1,876,229,000

Q4 2025 revenue $468.7M, full-year $1.876B. Net loss $429.1M Q4, $579.4M full year.
Adjusted EBITDA $37.8M (8.1% margin) Q4; $151.2M (8.1% margin) full year.
Performance Suite average members 6,482 for year; $900M new Performance Suite revenue for 2026.
2026 revenue growth guidance ~30%; first-half Adj. EBITDA pressured by reservering and membership declines.
Medical expense ratio 90.2% Q4; 80.5% full year (excl. ECP 94.8% and 89.0%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.